These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36 related articles for article (PubMed ID: 39118052)
1. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052 [TBL] [Abstract][Full Text] [Related]
2. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients. Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783 [TBL] [Abstract][Full Text] [Related]
3. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis. Veronese N; Di Gennaro F; Frallonardo L; Ciriminna S; Papagni R; Carruba L; Agnello D; De Iaco G; De Gennaro N; Di Franco G; Naro L; Brindicci G; Rizzo A; Bavaro DF; Garlisi MC; Santoro CR; Signorile F; Balena F; Mansueto P; Milano E; Giannitrapani L; Fiordelisi D; Mariani MF; Procopio A; Lattanzio R; Licata A; Vernuccio L; Amodeo S; Guido G; Segala FV; Barbagallo M; Saracino A Sci Rep; 2024 Apr; 14(1):9303. PubMed ID: 38654033 [TBL] [Abstract][Full Text] [Related]
4. Remdesivir for the treatment of COVID-19. Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582 [TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study. Rajme-López S; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; Tello-Mercado AC; Tepo-Ponce KM; Segura-Ortíz Z; López-Aguirre A; Gutiérrez-Mazariegos ODR; Lazcano-Delgadillo O; Nares-López R; González-Lara MF; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; Ruíz-Palacios GM Ther Adv Infect Dis; 2024; 11():20499361241236582. PubMed ID: 38545451 [TBL] [Abstract][Full Text] [Related]
6. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge. Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438 [TBL] [Abstract][Full Text] [Related]
7. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912 [TBL] [Abstract][Full Text] [Related]
8. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095 [TBL] [Abstract][Full Text] [Related]
9. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Butler CC; Hobbs FDR; Gbinigie OA; Rahman NM; Hayward G; Richards DB; Dorward J; Lowe DM; Standing JF; Breuer J; Khoo S; Petrou S; Hood K; Nguyen-Van-Tam JS; Patel MG; Saville BR; Marion J; Ogburn E; Allen J; Rutter H; Francis N; Thomas NPB; Evans P; Dobson M; Madden TA; Holmes J; Harris V; Png ME; Lown M; van Hecke O; Detry MA; Saunders CT; Fitzgerald M; Berry NS; Mwandigha L; Galal U; Mort S; Jani BD; Hart ND; Ahmed H; Butler D; McKenna M; Chalk J; Lavallee L; Hadley E; Cureton L; Benysek M; Andersson M; Coates M; Barrett S; Bateman C; Davies JC; Raymundo-Wood I; Ustianowski A; Carson-Stevens A; Yu LM; Little P; Lancet; 2023 Jan; 401(10373):281-293. PubMed ID: 36566761 [TBL] [Abstract][Full Text] [Related]
10. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19. Lim S; Tignanelli CJ; Hoertel N; Boulware DR; Usher MG Open Forum Infect Dis; 2022 Aug; 9(8):ofac389. PubMed ID: 36000003 [TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836 [TBL] [Abstract][Full Text] [Related]